Dermata Therapeutics, Inc.
DRMA
$5.50
-$0.33-5.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.33M | -11.46M | -12.29M | -11.27M | -9.82M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 127.20K | 107.60K | 657.60K | 756.30K | 866.50K |
| Change in Net Operating Assets | -755.60K | 956.50K | 466.80K | 1.12M | 1.20M |
| Cash from Operations | -10.96M | -10.39M | -11.16M | -9.40M | -7.75M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13.09M | 15.50M | 6.96M | 8.91M | 4.36M |
| Repurchase of Common Stock | -616.50K | -69.40K | -69.40K | -800.00 | -36.20K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 19.50K | -50.50K | 0.00 | 0.00 | -70.00K |
| Cash from Financing | 12.49M | 15.38M | 6.89M | 8.91M | 4.26M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.53M | 4.99M | -4.28M | -487.70K | -3.49M |